Flow Cytometric Enumeration of Antigen-Specific T Lymphocytes

Cytometry Part A

Volumn 58, Issue 1, 2004, Pages 79-86

  Gratama, J W ^a   Kern, F ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR;

ANTIGEN SPECIFICITY; CELL STIMULATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LATENT VIRUS INFECTION; LYMPHOCYTE CULTURE; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIREMIA; VIRUS CARRIER; VIRUS INFECTION; VIRUS LOAD;

EID: 1542724583     PISSN: 15524922     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.a.90005     Document Type: Review

References (102)

1. Maier B, Buhring HJ, Simon M, Eichmann K, Melchers I. Limiting dilution analysis of proliferating and helper T cells in the in vivo immune response to KLH: derepression of helper T cells at moderately increased frequencies. J Mol Cell Immunol 1986;2:293-305.
2. Owen JA, Allouche M, Doherty PC. Limiting dilution analysis of the specificity of influenza-immune cytotoxic T cells. Cell Immunol 1982;67:49-59.
3. Maino VC, Suni MA, Ruitenberg JJ. Rapid flow cytometric method for measuring lymphocyte subset activation. Cytometry 1995;20: 127-133.
4. Chang TW, McKinney S, Liu V, Kung PC, Vilcek J, Le J. Use of monoclonal antibodies as sensitive and specific probes for biologically active human γ-interferon. Proc Natl Acad Sci USA 1984;81: 5219-5222.
5. Inoue M, Kakumu S, Yoshioka K, Tsutsumi Y, Wakita T, Arao M. Hepatitis B core antigen-specific IFN-γ production of peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection. J Immunol 1989;142:4006-4011.
6. + T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2-1-binding melanoma and viral peptide antigens. J Immunol Methods 1996;191:131-142.
7. + T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 1997;3: 221-226.
8. Maino VC, Picker LJ. Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Cytometry 1998;34:207-215.
9. + T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 1997;99:1739-1750.
10. Manz R, Assenmacher M, Pfluger E, Miltenyi S, Radbruch A. Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix. Proc Natl Acad Sci USA 1995;92: 1921-1925.
11. + T cells based on cytokine secretion. Eur J Immunol 1999;29:4053-4059.
12. Assenmacher M, Scheffold A, Schmitz J, Segura Checa JA, Miltenyi S, Radbruch A. Specific expression of surface interferon-γ on interferon-γ producing T cells from mouse and man. Eur J Immunol 1996; 26:263-267.
13. Kern F, Surel IP, Brock C, Freistedt B, Radtke, H, Scheffold A, Blasczyk R, Reinke P, Schneider-Mergener J, Radbruch A, Walden P, Volk HD. T-cell epitope mapping by flow cytometry. Nat Med 1998;4:975-978.
14. Kern F, Faulhaber N, Frömmel C, Khatamzas E, Prösch S, Schönemann C, Kretzschmar I, Volkmer-Engert R, Volk HD, Reinke P. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000;30:1676-1682.
15. Matsui K, Boniface JJ, Reay PA, Schild H, Fazekas de St. Groth B. Low affinity interaction of peptide-MHC complexes with T cell receptors. Science 1991;254:1788-1791.
16. Altman J, Moss PAH, Goulder P, Barouch D, McHeyzer-Williams M, Bell JI, McMichael AJ, Davis, MM. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals. Science 1996;274:94-96.
17. + T cells proliferating in response to influenza A antigen. J Clin Invest 1999;104:R63-R67.
18. Hanke T, Takizawa H, McMahon CW, Busch DH, Pamer EG, Miller JD, Altman JD, Liu Y, Cado D, Lemonnier FA, Bjorkman PJ, Raulet DH. Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. Immunity 1999;11:67-77.
19. Matsuda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, Wang CR, Koezuka Y, Kronenberg M. Tracking the response of natural killer T cells to a glycolipid antigen using C1d tetramers. J Exp Med 2000;192:741-754.
20. + cytolytic T lymphocytes. Proc Natl Acad Sci USA 2003;100:10896-10901.
21. Wu J, Groh V, Spies T. T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial γδ T cells. J Immunol 2002;169:1236-1240.
22. Howard MC, Spack EG, Choudhury K, Greten TF, Schneck JP. MHC-based diagnostics and therapeutics - clinical applications for disease-linked genes. Immunol Today 1999;20:161-165.
23. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002;25:97-138.
24. Walker EB, Disis ML. Monitoring immune responses in cancer patients receiving tumor vaccines. Int Rev Immunol 2003;22:283-319.
25. + T lymphocytes using tetramer technology and single-platform absolute T-cell counting. J Biol Regul Homeost Agents 2003;17:268-278.
26. Mandy FF, Bergeron M, Recktenwald D, Izaguirre C. A simultaneous three-color T cell subsets analysis with single laser flow cytometers using T cell gating protocol. J Immunol Methods 1992;156:151-162.
27. Engleman EG, Fong L. Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients. Clin Immunol 2003;106:10-15.
28. Schnizlein-Bick CT, Spritzler J, Wilkening CL, Nicholson JKA, O'Gorman MRG, Site Investigators, and the NIAID DAIDS New Technologies Evaluation Group. Evaluation of TruCount absolute-count tubes for determining CD4 and CD8 cell numbers in human immunodeficiency virus-positive adults. Clin Diagn Lab Immunol 2000;7:336-343.
29. Reimann KA, O'Gorman MRG, Spritzler J, Wilkening CL, Sabath DE, Helm K, Campbell DE, and the NIAID DAIDS New Technologies Evaluation Group. Multisite comparison of CD4 and CD8 T-lymphocyte counting by single- versus multiple-platform methodologies: evaluation of Beckman Coulter Flow-Count fluorospheres and the tetraONE system. Clin Diagn Lab Immunol 2000;7:344-351.
30. + T cells through the combination of MHC class I and intracellular staining. J Immunol Methods 2002;268:9-19.
31. Picker LJ, Singh MK, Zdraveski Z, Treer JR, Waldrop SL, Bergstresser PR, Maino VC. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 1995;86:1408-1419.
32. Suni MA, Picker LJ, Maino VC. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods 1998;212:89-98.
33. + T cells. Cytometry 2000; 40:60-68.
34. Braciale TJ, Morrison LA, Sweetser MT, Sambrook J, Gething MJ, Braciale VL. Antigen presentation pathways to class I and II MHC-restricted T lymphocytes. Immunol Rev 1987;98:95-114.
35. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 1996;17:131-137.
36. + T cell cross-priming with exogenous antigens. J Immunol 2001;166:7268-7275.
37. + stem and progenitor cells by flow cytometry - Time to let go! Cytometry 1998;34:280-283.
38. O'Gorman MRG, Thomas J. Isotype controls - Time to let go? Cytometry 1999;38:78-80.
39. Maecker HT, Dunn HS, Suni MA, Khatamzas E, Pitcher CJ, Bunde T, Persaud N, Trigona W, Fu TM, Sinclair E, Bredt BM, McCune JM, Maino VC, Kern F, Picker LJ. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001;255:27-40.
40. Kern F, Bunde T, Faulhaber N, Kiecker F, Khatamzas E, Rudawski IM, Pruss A, Gratama JW, Volkmer-Engert R, Ewert R, Reinke P, Volk HD, Picker LJ. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 2002;185:1709-1716.
41. + T lymphocytes with changes in viral load. J Immunol 2000;165:1692-1704.
42. + T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency. J Virol 2000;74:4127-4138.
43. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF, McMichael AJ. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-2106.
44. + T-lymphocyte populations are related to plasma viral load. J Clin Immunol 2002;22:363-374.
45. Ogg GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Hurley A, Markowitz M, Ho DD, McMichael AJ, Nixon DF. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999;73:797-800.
46. + T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol 1999;162:1780-1788.
47. Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, Walker BD. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol 1999;73:6721-6728.
48. + T cells. Eur J Immunol 2002;32:1080-1089.
49. + T cells in HIV-infected progressors and long-term nonprogressors. J Immunol 2000;165:1082-1092.
50. + T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000;192:63-75.
51. + T cell expansions: evidence for impaired CTL effector function. Eur J Immunol 2001;31:677-686.
52. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999;5:518-525.
53. + HIV-specific T cells during progression to AIDS. Blood 2002;99:2505-2511.
54. + T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. Transplantation 2000;69:2243-2250.
55. + cytotoxic T-lymphocytes in liver transplant recipients. Transplantation 2000;69:2251-2259.
56. + T lymphocytes in healthy seropositive donors. J Virol 2000;74:8140-8150.
57. + T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998;187:1395-1402.
58. + T cells specific for EBV in healthy virus carriers. J Immunol 1999;162:1827-1835.
59. + T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002;195:893-905.
60. Dunn HS, Haney DJ, Ghanekar SA, Stepick-Biek P, Lewis DB, Maecker HT. Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J Infect Dis 2002;186:15-22.
61. Asanuma H, Sharp M, Maecker HT, Maino VC, Arvin AM. Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis 2000;181:859-866.
62. + T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003;101:4290-4297.
63. + T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001;98:1358-1364.
64. + T cells. Blood 2002; 100:3690-3697.
65. + T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 2001;98:146-155.
66. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998;4:953-956.
67. + T cell counts and recurrent retinitis. J Infect Dis 2001;183:1285-1289.
68. Hebart H, Daginik S, Stevanovic S, Grigoleit U, Dobler A, Baur M, Rauser G, Sinzger C, Jahn G, Loeffler J, Kanz L, Rammensee HG, Einsele H. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferonγ-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002;99:3830-3837.
69. + T cells associated with the control of infection. Gastroenterology 1999;117:1386-1396.
70. + cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000;191:1269-1280.
71. Matsumura S, Yamamoto K, Shimada N, Okano N, Okamoto R, Suzuki T, Hakoda T, Mizuno M, Higashi T, Tsuji T. High frequency of circulating HBcAg-specific CD8 T cells in hepatitis B infection: a flow cytometric analysis. Clin Exp Immunol 2001;124:435-444.
72. + T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 1999;96:5692-5697.
73. Lechner F, Wong DKH, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-1512.
74. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Liénard D, Cerottini JC, Cerundolo V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:1641-1650.
75. + T cells in melanoma patients. J Immunol 2000;165: 533-538.
76. Anichini A, Molla A, Mortarini R, Tragni G, Bersani I, Di Nicola M, Gianni AM, Pilotti S, Dunbar R, Cerundolo V, Parmiani G. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 1999;190:651-667.
77. Ogg GS, Dunbar PR, Romero P, Chen JL, Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998;188:1203-1208.
78. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999;190:705-715.
79. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogenous populations using peptide-MHC tetramers. J Immunol 1999;162:2227-2234.
80. Valmori D, Pittet MJ, Vonarbourg C, Rimoldi D, Liénard D, Speiser D, Dunbar R, Cerundolo V, Cerottini JC, Romero P. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A* 0201-associated tyrosinase peptide 368-376. Cancer Res 1999;59:4050-4055.
81. Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Brichard V, Boon T. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene AMGE-3. Proc Natl Acad Sci USA 2001;98:10290-10295.
82. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-685.
83. + T cells. J Immunol 2000;165:2287-2296.
84. + T cells after vaccination with antigenic peptide. Clin Cancer Res 2001;7: 796s-803s.
85. + T-cell responses. J Clin Oncol 2003;21:1562-1573.
86. Dunbar PR, Smith CL, Chao D, Salio M, Shepherd D, Mirza F, Lipp M, Lanzavecchia A, Sallusto F, Evans A, Russell-Jones R, Harris AL, Cerundolo V. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol 2000;165:6644-6652.
87. Pittet MJ, Zippelius A, Speiser DE, Assenmacher M, Guillaume P, Valmori D, Liénard D, Lejeune F, Cerottini JC, Romero P. Ex vivo IFN-γ secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol 2001;166:7634-7640.
88. - effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 2002;62:1743-1750.
89. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute leukemia. Blood 2002;100:2132-2137.
90. Karanikas V, Lodding J, Maino VC, McKenzie IFC. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin Cancer Res 2000;6:829-837.
91. Maecker HT, Auffermann-Gretzinger S, Nomura L, Liso A, Czerwinski DK, Levy R. Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry. Clin Cancer Res 2001;7:902s-908s.
92. Kwok WW, Liu AW, Novak EJ, Gebe JA, Ettinger RA, Nepom GT, Reymond SN, Koelle DM. HLA-DQ tetramers identify epitope-specific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: direct detection of immunodominant antigen-responsive cells. J Immunol 2000;164:4244-4249.
93. Meyer AL, Trollmo C, Crawford F, Marrack P, Steere AC, Hubert BT, Kappler J, Hafler DA. Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc Natl Acad Sci USA 2000;97:11433-11438.
94. Liu CP, Jiang K, Wu CH, Lee WH, Lin WJ. Detection of glutamic acid decarboxylase-activated T cells with I-Ag7 tetramers. Proc Natl Acad Sci USA 2000;97:14596-14601.
95. Quarsten H, McAdam SN, Jensen T, Arentz-Hansen H, Molberg O, Lundin KE, Sollid LM. Staining of celiac disease-relevant T cells by peptide-DQ2 multimers. J Immunol 2000;167:4861-4868.
96. Buckner JH, Van LM, Kwok WW, Tsarknaridis L. Identification of type II collagen peptide 261-273 specific T cell clones in a patient with relapsing polychondritis. Arthritis Rheum 2002;46:238-244.
97. Engleman EG, Fong L. Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients. Clin Immunol 2003;106:10-15.
98. NCCLS. Performance of single cell immune response assays; proposed guideline. NCCLS document I/LA26-P (ISBN 1-56238-000-0). NCCLS, Wayne, PA, 2003.
99. Hoffmeister B, Kiecker F, Tesfa L, Volk HD, Picker LJ, Kern F. Mapping T cell epitopes by flow cytometry. Methods 2003;29:270-281.
100. Bissinger AL, Rauser G, Hebart H, Frank F, Jahn G, Einsele H. Isolation and expansion of human cytomegalovirus-specific cytotoxic T lymphocytes using interferon-γ secretion assay. Exp Hematol 2002;30:1178-1184.
101. Knabel M, Franz TJ, Schiemann M, Wulf A, Villmow B, Schmidt B, Bernhard H, Wagner H, Busch DH. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 2002;8:631-637.
102. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Löffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, Kleihauer A, Frank F, Jahn G, Hebart H. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99:3916-3922.